EDITORIAL SECTION

Codexis Inc NASDAQ CDXS a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing today announced an agreement with a pioneering siRNA drug innovator

Lifecore Biomedical Inc Nasdaq LFCR today announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to million assuming full achievement

Genentech a member of the Roche Group SIX RO ROP OTCQX RHHBY today broke ground on a million expansion of its manufacturing facility in Hillsboro Oregon advancing plans announced in August to increase

Eli Lilly and Company is launching today the Lilly Change the Course Commitment a new global health initiative that aims to achieve parity in patients treated with Lillys innovative diabetes and obesity medicines This means treating as many people with diabetes and obesity in resourcelimited

Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to million subject to the achievement of certain performance milestones

Meitheal Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved a highconcentration formulation of YUSIMRY adalimumabaqvh an interchangeable biosimilar to Humira

Merck known as MSD outside of the United States and Canada and SciBrunch Therapeutics Co Ltd SciBrunch today announced that they have entered into an exclusive global license agreement for SPR an investigational preclinical oral KRAS GD ON inhibitor

The US Food and Drug Administration FDA has granted Breakthrough Therapy designation to Glycomines investigational GLM for the treatment of phosphomannomutase congenital disorder of glycosylation PMMCDG

Elevar Therapeutics has announced that the US Food and Drug Administration FDA has approved LYRFIGTU lirafugratinib as a treatment option for patients with cholangiocarcinoma CCA with an FGFR fusion or other rearrangement

The US Food and Drug Administration FDA has granted Orphan Drug Designation to Kedrion Biopharmas QIVIGY immune globulin intravenous human solution for the potential treatment of Stiff Person Syndrome SPS